Stroma-derived Neoplasms of Lymphoid Tissues
Stroma-derived neoplasms of lymphoid tissues represent a unique category of tumors arising from the stromal component of lymphoid tissues. Our company is dedicated to advancing drug and therapy development services for stroma-derived neoplasms of lymphoid tissues, offering innovative solutions to combat these challenging diseases.
Overview of Stroma-derived Neoplasms of Lymphoid Tissues
Stroma-derived neoplasms of lymphoid tissues are a new category in the 5th edition of the World Health Organization classification of hemolymph tumors. Stroma-derived neoplasms of lymphoid tissues refer to a distinct category of tumors that arise from the stromal component of lymphoid tissues, including lymph nodes and spleen. The stroma encompasses various non-hematopoietic cell types, such as fibroblasts, endothelial cells, and follicular dendritic cells. These neoplasms exhibit unique clinicopathological features and require specialized approaches for understanding and therapy development.
Fig.1 The typical pathological features of littoral cell angioma (LCA). (Wang, Weijie, et al., 2022)Classification of Stroma-derived Neoplasms of Lymphoid Tissues
| WHO Classification, 5th edition | WHO Classification, revised 4th edition |
|---|---|
| Mesenchymal dendritic cell neoplasms | |
| Follicular dendritic cell sarcoma | (Same) |
| Fibroblastic reticular cell tumour | (Same) |
| EBV-positive inflammatory follicular dendritic cell sarcoma | Inflammatory pseudotumour-like follicular/fibroblastic dendritic cell sarcoma |
| Myofibroblastic tumour | |
| Intranodal palisaded myofibroblastoma | Not previously included |
| Spleen-specific vascular-stromal tumours | |
| Splenic vascular-stromal tumours | |
| Splenic hamartoma | Not previously included |
| Littoral cell angioma | Not previously included |
| Sclerosing angiomatoid nodular transformation of spleen | Not previously included |
Therapy Development for Stroma-derived Neoplasms of Lymphoid Tissues
VEGF Targeted Therapies
One promising target for stroma-derived neoplasms (lymphoid tissues) therapy development involves the inhibition of angiogenesis, specifically targeting vascular endothelial growth factor (VEGF) signaling pathways. Early research evaluating anti-angiogenic agents, such as bevacizumab, have shown encouraging results, including reductions in tumor size and improved outcomes.
Wnt Targeted Therapies
The Wnt signaling pathway is one of the key targets. Somatic mutations in the CTNNB1 gene, a crucial component of the Wnt pathway, have been identified in intranodal palisaded myofibroblastoma (IPM). By inhibiting the aberrant activation of this pathway, our company aims to halt tumor development and progression. The development of small molecule inhibitors and monoclonal antibodies targeting these alterations holds promise for disrupting aberrant signaling in IPM and providing effective therapy options.
MAPK Targeted Therapies
Extensive research has shed light on the genetic alterations and signaling pathways associated with EBV-positive inflammatory follicular dendritic cell sarcoma. One promising target lies within the MAPK pathway, which plays a vital role in cell growth, division, and survival.
Our Services
Through comprehensive genomic profiling and advanced bioinformatics analyses, we identify potential therapeutic targets and design innovative therapy development strategies for stroma-derived neoplasms of lymphoid tissues. Our experienced team of researchers and scientists work hard together to enhance one-stop diagnostics and therapeutic development services.
Our Disease Research Types
- Follicular dendritic cell sarcoma
- Fibroblastic reticular cell tumour
- EBV-positive inflammatory follicular dendritic cell sarcoma
- Intranodal palisaded myofibroblastoma
- Splenic hamartoma
- Littoral cell angioma
- Sclerosing angiomatoid nodular transformation of spleen
Our Therapy Development Platforms
In addition, our company provides state-of-the-art animal model development services using genetic engineering and patient-derived xenograft (PDX) technology. These models enable researchers to study disease mechanisms and preclinical testing. Our rich range of animal species allows us to enhance pharmacokinetic analysis and drug safety evaluation services.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Wang, Weijie, et al. "Clinical landscape of littoral cell Angioma in the spleen based on a comprehensive analysis." Frontiers in Oncology 12 (2022): 790332.
- Baber, Alistair, et al. "EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Spleen: Report of an Aggressive Form With Molecular Characterization." International Journal of Surgical Pathology 32.1 (2024): 150-154.
- Alaggio, Rita, et al. "The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms." Leukemia 36.7 (2022): 1720-1748.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.